Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

HaiHe Bio Completes $171 Million B Round to Advance Novel Candidates

publication date: Jul 24, 2020

Shanghai HaiHe Biopharma completed a $171 million Series C round led by Warburg Picus to advance its portfolio of innovative drugs. The company has ten candidates in clinical trials, including three at Phase III stage or beyond. HaiHe has partnered with Shanghai Institute of Materia Medica, Chinese Academy of Science to develop novel cancer drugs for global markets. In 2018, HaiHe merged with RMX (Shanghai) Pharmaceutical Technology. Last year, the company raised $147 million in an A round. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital